Compounds > ono-5334
Page last updated: 2024-11-12

ono-5334

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID11582982
CHEMBL ID4303672
SCHEMBL ID3629499
MeSH IDM0560831

Synonyms (17)

Synonym
SCHEMBL3629499
ono-5334
n-((1s)-3-{(2z)-2-((4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene) hydrazino}-2,3-dioxo-1-(tetrahydro-2h-pyran-4-yl)propyl)cycloheptane carboxamide
AKOS032954060
unii-9tdn93l9fn
HY-108044
n-[(1s)-3-[(2z)-2-[(4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazinyl]-1-(oxan-4-yl)-2,3-dioxopropyl]cycloheptanecarboxamide
n-((1s)-3-((2z)-2-((4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene) hydrazino)-2,3-dioxo-1-(tetrahydro-2h-pyran-4-yl)propyl)cycloheptane carboxamide
2h-pyran-4-propanoic acid, beta-((cycloheptylcarbonyl)amino)tetrahydro-alpha-oxo-, (2z)-2-((4r)-3,4-dimethyl-2-thiazolidinylidene)hydrazide, (betas)-
cid 11582982
CHEMBL4303672
CS-0027222
MS-27868
9tdn93l9fn ,
620614-15-5
n-((1s)-3-((2z)-2-((4r)-3,4-dimethyl-1,3-thiazolidin-2-ylidene)hydrazino)-2,3-dioxo-1-(tetrahydro-2h-pyran-4yl)propyl)cycloheptanecarboxamide
BO177436

Research Excerpts

Pharmacokinetics

The purpose of the study was to clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers. The pharmacokinetics and the pharmacodynamic effects on biochemical markers of bone turnover were investigated.

ExcerptReferenceRelevance
" The pharmacokinetics and the pharmacodynamic effects on biochemical markers of bone turnover of the new cathepsin K inhibitor, ONO-5334, were investigated in a multiple ascending dose, phase 1 study."( Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M, 2012)		0.79
"The purpose of the study was clarify the effect of the cathepsin K inhibitor ONO-5334 on bone resortion markers using sustained release (SR) formulations with different pharmacokinetic (PK) patterns, and identify the optimal SR formulation."( Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns.
Deacon, S; Hashimoto, Y; Honda, N; Sekiya, N; Tanaka, M; Yamamoto, M, 2014)		0.9
" There was no significant difference in PK and pharmacodynamic potency (IC50 ) between Caucasian and Japanese."( Population pharmacokinetic and pharmacodynamic modeling of different formulations of ONO-5334, cathepsin K inhibitor, in Caucasian and Japanese postmenopausal females.
Deacon, S; Hasegawa, C; Honda, N; Ieiri, I; Nagase, S; Ogawa, M; Ohno, T; Ohyama, M; Small, M; Umemura, T, 2014)		0.63

Dosage Studied

Morning dosing of ONO-5334 is more efficacious at reducing markers of bone turnover in healthy postmenopausal women.

ExcerptRelevanceReference
" Multiple dosing with ONO-5334 100 mg resulted in considerable suppression of bone resorption markers with no appreciable effects on bone formation markers (B-ALP, OC) or osteoclast number (TRAP5b)."( Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study.
Deacon, S; Hashimoto, Y; Kuwayama, T; Nagase, S; Ohyama, M; Small, M, 2012)		0.9
" These levels were consistently decreased below pre-dose levels by repeated oral dosing with ONO-5334 for 7 days."( Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism.
Hashimoto, Y; Kawabata, K; Kawada, N; Kayasuga, R; Kunishige, A; Mori, H; Nakanishi, Y; Nishikawa, S; Ochi, Y; Sugitani, M; Tanaka, M; Yamada, H, 2011)		0.98
" Repeated SRT dosing did not significantly affect PK, although C 24h increased slightly."( Bone turnover markers and pharmacokinetics of a new sustained-release formulation of the cathepsin K inhibitor, ONO-5334, in healthy post-menopausal women.
Deacon, S; Hashimoto, Y; Kuwayama, T; Manako, J; Nagase, S; Ohyama, M; Sharpe, J; Small, M, 2015)		0.63
"Morning dosing of ONO-5334 is more efficacious at reducing markers of bone turnover in healthy postmenopausal women than evening dosing."( Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial.
Deacon, S; Dijk, DJ; Eastell, R; Greenwood, A; Sharpe, J; Small, M; Tanimoto, M; Yamada, H; Yuba, M, 2016)		1.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's19 (100.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.22 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (63.16%)5.53%
Reviews2 (10.53%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (26.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		5.66321,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
thiazolidines
Thiazolidines: Reduced (protonated) form of THIAZOLES. They can be oxidized to THIAZOLIDINEDIONES.		11.331912thiazolidine
odanacatib
odanacatib: a selective inhibitor of cathepsin K for the treatment of post-menopausal osteoporosis; structure in first source		4.120
ConditionIndicatedRelationship StrengthStudiesTrials
Bone Loss, Perimenopausal
[description not available]		010.11108
Osteoporosis, Postmenopausal
Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.		010.11108
Bone Loss, Osteoclastic
[description not available]		09.1374
Age-Related Osteoporosis
[description not available]		05.8742
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		05.8742
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.921